Published in Nat Struct Mol Biol on December 08, 2013
Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem (2014) 1.61
Regulation of hepatic energy metabolism and gluconeogenesis by BAD. Cell Metab (2014) 0.89
Z-Selective olefin metathesis on peptides: investigation of side-chain influence, preorganization, and guidelines in substrate selection. J Am Chem Soc (2014) 0.82
Regulation of mitochondrial nutrient and energy metabolism by BCL-2 family proteins. Trends Endocrinol Metab (2015) 0.80
Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1. ChemMedChem (2015) 0.80
Redefining the BH3 Death Domain as a 'Short Linear Motif'. Trends Biochem Sci (2015) 0.77
Phospho-BAD BH3 mimicry protects β cells and restores functional β cell mass in diabetes. Cell Rep (2015) 0.77
Anti-incretin, Anti-proliferative Action of Dopamine on β-Cells. Mol Endocrinol (2015) 0.76
Biochemical and biophysical investigations of the interaction between human glucokinase and pro-apoptotic BAD. PLoS One (2017) 0.75
An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom (1994) 45.51
Mechanisms for insulin resistance: common threads and missing links. Cell (2012) 6.85
BAX activation is initiated at a novel interaction site. Nature (2008) 6.07
BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature (2003) 4.80
Allosteric activators of glucokinase: potential role in diabetes therapy. Science (2003) 3.97
Diabetes mellitus and the β cell: the last ten years. Cell (2012) 3.31
Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med (2008) 2.78
Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov (2009) 2.60
Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure (2004) 2.55
BAD: undertaker by night, candyman by day. Oncogene (2008) 2.47
Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab (2012) 2.46
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat (2009) 2.29
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest (2012) 2.17
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab (2010) 2.05
Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes (1999) 1.87
A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology (2005) 1.75
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.70
Direct activation of full-length proapoptotic BAK. Proc Natl Acad Sci U S A (2013) 1.53
Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. Proc Natl Acad Sci U S A (1993) 1.40
Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes (2004) 1.36
Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia (1999) 1.33
Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia (2003) 1.30
Variable effects of maturity-onset-diabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme. Biochem J (1995) 1.30
Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab (2011) 1.24
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem (2012) 1.19
Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chem Biol (2010) 1.11
Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2). Biochem J (1997) 1.07
Demonstration of a slow conformational change in liver glucokinase by fluorescence spectroscopy. J Biol Chem (1990) 1.07
Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med (2010) 1.07
Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states. Biochemistry (2009) 1.07
Insulin signaling regulates mitochondrial function in pancreatic beta-cells. PLoS One (2009) 1.03
An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem (2006) 1.03
Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem (2008) 1.02
Direct evidence of conformational heterogeneity in human pancreatic glucokinase from high-resolution nuclear magnetic resonance. Biochemistry (2010) 1.01
Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab (2002) 1.00
Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia (2007) 1.00
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem (2009) 1.00
The active conformation of human glucokinase is not altered by allosteric activators. Acta Crystallogr D Biol Crystallogr (2011) 0.99
Global fit analysis of glucose binding curves reveals a minimal model for kinetic cooperativity in human glucokinase. Biochemistry (2010) 0.95
Homotropic allosteric regulation in monomeric mammalian glucokinase. Arch Biochem Biophys (2011) 0.94
Methods of human islet culture for transplantation. Cell Transplant (2004) 0.92
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab (2013) 0.91
Glucose metabolism: key endogenous regulator of β-cell replication and survival. Diabetes Obes Metab (2012) 0.91
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab (2013) 0.87
Mutational analysis of allosteric activation and inhibition of glucokinase. Biochem J (2011) 0.87
Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations. J Biol Chem (2012) 0.87
Glucose modulation of glucokinase activation by small molecules. Biochemistry (2008) 0.86
Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. Mol Endocrinol (2009) 0.85
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine (2013) 0.85
Increased albumin concentration reduces apoptosis and improves functionality of human islets. Artif Cells Blood Substit Immobil Biotechnol (2008) 0.84
Susceptibility of glucokinase-MODY mutants to inactivation by oxidative stress in pancreatic β-cells. Diabetes (2011) 0.82
Glucokinase-activating ureas. Bioorg Med Chem Lett (2005) 0.81
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Int J Clin Pharmacol Ther (2012) 0.81
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle. Bioorg Med Chem Lett (2009) 0.78